Pharma Mar has filed a patent for form B of lurbinectedin, detailing a process to create a lyophilized pharmaceutical composition. The process involves washing, basifying, solubilizing, and freeze-drying to convert the crystalline form of lurbinectedin to an amorphous form. GlobalData’s report on Pharma Mar gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pharma Mar SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Pharma Mar, Cancer treatment biomarkers was a key innovation area identified from patents. Pharma Mar's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Lyophilized pharmaceutical composition of form b of lurbinectedin

Source: United States Patent and Trademark Office (USPTO). Credit: Pharma Mar SA

The patent application (Publication Number: US20230416276A1) describes a lyophilized pharmaceutical composition containing lurbinectedin, prepared through a specific process. The process involves steps such as washing the solution with water-immiscible solvents, basifying the solution to precipitate a crystalline form of lurbinectedin, and freeze-drying to convert it into an amorphous form. Additional steps include dissolving the crystalline form in an organic acid solution, mixing with an organic acid buffer and a bulking agent, and freeze-drying to obtain the final composition.

Furthermore, the composition must meet specific criteria, such as having a residual solvent content of no more than 0.5% wt/wt, total impurities not exceeding 1.9% wt/wt, and no more than 0.3% wt/wt of any individual unspecified impurity. The process also involves sterilization filtration before filling the solution into vials and freeze-drying. The use of specific organic acids, bases, and bulking agents is outlined, along with the pH ranges required for different solutions. Overall, the patent application provides a detailed and specific method for preparing a lyophilized pharmaceutical composition containing lurbinectedin, ensuring high quality and purity standards are met throughout the process.

To know more about GlobalData’s detailed insights on Pharma Mar, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies